ZOSUL Injection (Cefoperazone Sodium + Sulbactam Sodium)
Table of Content
ESBL-producing strains are a growing menace that increases the mortality risk by ˜2.6-fold as compared with non-ESBL-producing strains as well as prolongs the hospital stay by an average of 6 days. ESBLs infections are also associated with a high rate of treatment failure (42-100% mortality rate due to treatment failure). Among different antibiotics, beta-lactams account for approximately 50% of the global antibiotic consumption because of their proven efficacy and safety. Therefore, beta-lactam/beta-lactamase inhibitor combinations offer a potential alternative to newer cephalosporins. As ESBLs are generally susceptible to the available beta-lactamase inhibitors, such combinations are often seen as the only reliable antibacterials for the treatment of ESBL-producing bacterial infections. The combination (2:1) of cefoperazone (third-generation cephalosporin) and sulbactam (beta-lactamase inhibitor) is a rational combination that provides a solution for the treatment of bacterial infections caused by resistant pathogens. The rationale behind combining cefoperazone and sulbactam is as follows: Sulbactam prevents the destruction of cefoperazone by resistant organisms/beta-lactamases. Sulbactam also binds with some PBPs, thereby rendering sensitive strains more susceptible to cefoperazone-sulbactam than cefoperazone alone. Sulbactam reduces the minimum inhibitory concentrations (MICs) of cefoperazone by 4-fold. The addition of sulbactam to cefoperazone does not compromise the safety of the beta-lactam antibiotic. Ideal empirical therapy for life-threatening, difficult-to-treat infections ZOSUL 1.5 g for Injection is indicated for the treatment of the following infections: respiratory tract infections, skin and soft tissue infections, urinary tract infections, bone and joint infections, serious infections, intra-abdominal infections, gonorrhoea, pelvic inflammatory disease, endometritis, and other infections of the genital tract. The usual adult dose of ZOSUL 1.5 g (cefoperazone-sulbactam) is 3.0 to 6.0 g every 12 hours given either as an intravenous or intramuscular infusion over a period of 15-60 minutes. The reconstituted solution is stable for 7 days at 2° - 8°C and for 24 hours at 8° - 25°C. In severe or refractory infections, the daily dosage may be increased up to 12 gm (i.e. 8 gm of cefoperazone activity). The recommended maximum daily dosage of sulbactam is 4 gm. Dose modification of sulbactam is required in patients with renal impairment and the dosage should be adjusted in patients with a marked decrease in renal function (creatinine clearance <30 mL/min) to compensate for the reduced clearance of sulbactam. Dose modification may be necessary in cases of severe biliary obstruction, severe hepatic disease or in cases of renal dysfunction coexistent with either of those conditions. The dose should not exceed more than 2 gm/day of cefoperazone.
Cefoperazone Sodium Plus Sulbactam Sodium Injection
ZOSUL Injection 1.0 g
Each vial contains:
Cefoperazone Sodium equivalent to Cefoperazone, IP . 500 mg
Sulbactam Sodium equivalent to Sulbactam, USP . 500 mg
Each FFS vial contains
Sterile Water for Injections IP ........................................ 5 ml
ZOSUL Injection 1.5 g
Each vial contains:
Cefoperazone Sodium equivalent to Cefoperazone, IP . 1,000 mg
Sulbactam Sodium equivalent to Sulbactam, USP . 500 mg
Each FFS vial contains
Sterile Water for Injections IP ..................................... 10 ml
Powder for reconstitution and intravenous and intramuscular use only
The sulbactam sodium and cefoperazone sodium combination consists of a beta-lactamase inhibitor plus a beta-lactam.
This sulbactam/cefoperazone combination is available as a dry powder for reconstitution in a 1:1 ratio and 1:2 ratio.
The antibacterial component of sulbactam/cefoperazone is cefoperazone, a third-generation cephalosporin, which acts against sensitive organisms during the stage of active multiplication by inhibiting the biosynthesis of cell wall mucopeptide. Sulbactam does not possess any useful antibacterial activity, except against Neisseriaceae and Acinetobacter. However, biochemical studies with cell-free bacterial synthesis have shown it to be an irreversible inhibitor of most important beta-lactamases produced by beta-lactam antibiotic-resistant organisms.
The potential for sulbactam preventing the destruction of penicillins and cephalosporins by resistant organisms was confirmed in whole-organism studies using resistant strains in which sulbactam exhibited marked synergy with penicillins and cephalosporins. As sulbactam also binds with some penicillin binding proteins, sensitive strains are also often rendered more susceptible to sulbactam/cefoperazone than to cefoperazone alone.
The combination of cefoperazone and sulbactam is active against all organisms sensitive to cefoperazone. In addition, it demonstrates synergistic activity (up to 4-fold reduction in the minimum inhibitory concentrations for the combination versus those for each component) in a variety of organisms, most markedly the following:
Sulbactam/cefoperazone is active in vitro against a wide variety of clinically significant organisms:
Staphylococcus aureus, penicillinase and non-penicillinase-producing strains
Streptococcus pneumoniae (formerly Diplococcus pneumoniae)
Streptococcus pyogenes (Group A beta-haemolytic streptococci)
Streptococcus agalactiae (Group B beta-haemolytic streptococci)
Most other strains of beta-haemolytic streptococci
Many strains of Streptococcus faecalis (enterococcus)
Morganella morganii (formerly Proteus morganii)
Providencia rettgeri (formerly Proteus rettgeri)
Serratia species (including S. marcescens)
Salmonella and Shigella species
Pseudomonas aeruginosa and some other Pseudomonas species
Gram-negative bacilli (including Bacteroides fragilis, other Bacteroides species, and Fusobacterium species). Gram-positive and Gram-negative cocci (including Peptococcus, Peptostreptococcus and Veillonella species).
Gram-positive bacilli (including Clostridium, Eubacterium and Lactobacillus species).
Approximately 84% of the sulbactam dose and 25% of the cefoperazone doseadministered as sulbactam/cefoperazone is excreted by the kidneys. Most of theremaining dose of cefoperazone is excreted in the bile. After sulbactam/cefoperazone administration, the mean half-life for sulbactam is about 1 hour while that forcefoperazone is 1.7 hours. Serum concentrations have been shown to be proportional to the dose administered. These values are consistent with previously published values for these agents when given alone.
Mean peak sulbactam and cefoperazone concentrations after the administration of 2 g of sulbactam/cefoperazone (1 g sulbactam, 1 g of cefoperazone) intravenously over 5 minutes were 130.2 and 236.8 mcg/mL, respectively. This reflects the larger volume of distribution for sulbactam (Vd = 18.0 to 27.6 L) compared to cefoperazone (Vd = 10.2 to 11.3 L).
After intramuscular administration of 1.5 g cefoperazone sulbactam (0.5 g sulbactam, 1 g cefoperazone), peak serum concentrations of sulbactam and cefoperazone are seen from 15 minutes to 2 hours after administration. Mean peak serum concentrations were 19.0 and 64.2 mcg /mL for sulbactam and cefoperazone, respectively.
Both sulbactam and cefoperazone distribute well into a variety of tissues and fluids, including the bile, gall bladder, skin, appendix, fallopian tubes, ovary,uterus, and others.
There is no evidence of any pharmacokinetic drug interaction between sulbactam and cefoperazone when administered together in the form of sulbactam/cefoperazone.
After multiple dosing, no significant changes in the pharmacokinetics of either component of sulbactam/cefoperazone have been reported and no accumulation has been observed when administered every 8 to 12 hours.
Refer to DOSAGE AND ADMINISTRATION
In patients with different degrees of renal function administered sulbactam/cefoperazone, the total body clearance of sulbactam was highly correlated with estimated creatinine clearance. Patients who are functionally anephric showed a significantly longer half-life of sulbactam (mean 6.9 and 9.7 hours in separate studies). Hemodialysis significantly altered the half life, total body clearance, and volume of distribution of sulbactam. No significant differences have been observed in the pharmacokinetics of cefoperazone in renal failure patients.
The pharmacokinetics of sulbactam/cefoperazone have been studied in elderly individuals with renal insufficiency and compromised hepatic function. Both sulbactam and cefoperazone exhibited longer half-life, lower clearance, and larger volumes of distribution when compared to data from normal volunteers. The pharmacokinetics of sulbactam correlated well with the degree of renal dysfunction while for cefoperazone there was a good correlation with the degree of hepatic dysfunction.
Use in Children
Studies conducted in paediatrics have shown no significant changes in the pharmacokinetics of the components of sulbactam/cefoperazone compared to adult values. The mean half-life in children has ranged from 0.91 to 1.42 hours for sulbactam and from 1.44 to 1.88 hours for cefoperazone.
ZOSUL Injection is indicated for the treatment of the following infections when caused by susceptible organisms:
- Respiratory tract infections (upper and lower)
- Urinary tract infections (upper and lower)
- Peritonitis, cholecystitis, cholangitis, and other intra-abdominal infections
- Skin and soft tissue infections
- Bone and joint infections
- Pelvic inflammatory disease, endometritis, gonorrhoea, and other infections of the genital tract
Because of the broad spectrum of activity of sulbactam/cefoperazone, most infections can be treated adequately with this antibiotic combination alone. However, sulbactam/cefoperazone may also be used concomitantly with other antibiotics if such combinations are indicated. If an aminoglycoside is used, renal function should be monitored during the course of therapy.
Daily dosage recommendations for sulbactam/cefoperazone in adults are as follows:
Doses should be administered every 12 hours in equally divided doses.
In severe or refractory infections, the daily dosage of sulbactam/cefoperazone may be increased up to 8 g of the 1:1 ratio (i.e. 4 g of cefoperazone activity) or 12 g of the 1:2 ratio (i.e. 8 g of cefoperazone activity). Patients receiving the 1:1 ratio may require additional cefoperazone administered separately. Doses should be administered every 12 hours in equally divided doses.
The recommended maximum daily dosage of sulbactam is 4 g.
In febrile neutropenia, total daily dose can be administered twice or thrice a day in equally divided doses.
Dosage regimens of sulbactam/cefoperazone should be adjusted in patients witha marked decrease in renal function (creatinine clearance of less than 30 mL/min) tocompensate for the reduced clearance of sulbactam. Patients with creatinine clearances between 15 and 30 mL/min should receive a maximum of 1 g of sulbactam every 12 hours (maximum daily dosage of 2 g sulbactam), while patients with creatinine clearances of less than 15 mL/min should receive a maximum of 500 mg of sulbactam every 12 hours (maximum daily dosage of 1 g sulbactam). In severe infections it may be necessary to administer additional cefoperazone.The pharmacokinetic profile of sulbactam is significantly altered by haemodialysis. The serum half-life of cefoperazone is reduced slightly during haemodialysis. Thus, dosing should be scheduled to follow a dialysis period.
Cefoperazone is extensively excreted through the bile. The serum half life of cefoperazone is usually prolonged and urinary excretion of the drug increased in patients with hepatic disease and/or biliary obstruction. Even with severe hepatic dysfunction, therapeutic concentrations of cefoperazone are obtained in bile and only a 2 to 4 fold increase in half life is seen.
Dose modification may be necessary in cases of severe biliary obstruction, severe hepatic disease or in cases of renal dysfunction coexistent with either of those conditions.
In patients with hepatic dysfunction and concomitant renal impairment, cefoperazone serum concentrations should be monitored and dosage adjusted as necessary. In such cases, dosage should not exceed 2 g/day of cefoperazone without close monitoring of serum concentrations.
Daily dosage recommendations for sulbactam/cefoperazone in children are as follows:
Doses should be administered every 6 to 12 hours in equally divided doses.
In serious or refractory infections, these dosages may be increased up to 160 mg/kg/day or 240 mg/kg/day of the 1:2 ratio (160 mg/kg/day cefoperazone activity). Doses should be administered in two to four equally divided doses.
Use in Neonates
For neonates in the first week of life, the drug should be given every 12 hours. Themaximum daily dosage of sulbactam in paediatric patients should not exceed 80 mg/kg/day. If more than 80 mg/kg/day of cefoperazone activity is necessary, additional cefoperazone should be administered separately.
Sulbactam/cefoperazone is available in vials of 1.0 g and 1.5 g strengths, along with a 5 ml and 10 ml FFS vial of Sterile Water for injection for reconstitution.
of Sulbactam +
For intravenous infusion, each vial of sulbactam/cefoperazone should be reconstituted with the appropriate amount of 5% Dextrose in water, 0.9% Sodium Chloride Injection or Sterile Water for Injection, then further diluted to 20 mL with the same solution, and followed by administration over 15 to 60 minutes. Lactated Ringerssolution is a suitable vehicle for intravenous infusion, but it is not, however, for initialreconstitution.
For intravenous injection, each vial should be reconstituted as above and administered over a minimum of 3 minutes.
Sulbactam/cefoperazone has been shown to be compatible with water for injection, 5% dextrose, normal saline, 5% dextrose in 0.225% saline, and 5% dextrose in normals aline at concentrations of 10 mg cefoperazone and 5 mg sulbactam per mL and up to 250 mg cefoperazone and 125 mg sulbactam per mL.
Lactated Ringers Solution
Sterile Water for Injection should be used for reconstitution (see INCOMPATIBILITY, Lactated Ringers Solution). A two-step dilution is required using Sterile Water for Injection (as shown in the table above) first, which is then further diluted with Lactated Ringers Solution to get a sulbactam concentration of 5 mg/mL (use 2 mL initial dilution in 50 mL or 4 mL initial dilution in 100 mL Lactated Ringers Solution).
Lidocaine Hydrochloride (HCl)
Sterile Water for Injection should be used for reconstitution (see INCOMPATIBILITY, Lidocaine HCl). For a concentration of cefoperazone of 250 mg/mL or larger, a two-step dilution is required using Sterile Water for Injection (shown in the table above) first, which is then further diluted with 2% lidocaine HCl to yield solutions containing up to 250 mg cefoperazone and 125 mg sulbactam per mL in, approximately, a 0.5% lidocaine HCl solution.
Lidocaine HCl 2% is a suitable vehicle for intramuscular administration; however, it is not for initial reconstitution.
ZOSUL Injection is contraindicated in patients with a known allergy to penicillins, sulbactam, cefoperazone or any of the cephalosporins.
Serious and, occasionally, fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam or cephalosporin therapy. These reactions are more apt to occur in individuals with a history of hypersensitivity reactions to multiple allergens. If an allergic reaction occurs, the drug should be discontinued and the appropriate therapy instituted.
Serious anaphylactic reactions require immediate emergency treatment withepinephrine. Oxygen, intravenous steroids and airway management, includingintubation, should be administered as indicated. As with other antibiotics, vitamin K deficiency has occurred in a few patients treated with cefoperazone. The mechanism is most probably related to the suppression of gut flora, which normally synthesize this vitamin. Those at risk include patients with poor diet, malabsorption states (e.g. cystic fibrosis) and patients on prolonged intravenous alimentation regimens. Prothrombin time should be monitored in these patients and in patients receiving anticoagulant therapy, and exogenous vitamin K administered as indicated.
As with other antibiotics, overgrowth of non-susceptible organisms may occur during the prolonged use of sulbactam/cefoperazone. Patients should be observed carefullyduring the treatment. As with any potent systemic agent, it is advisable to checkperiodically for organ system dysfunction during extended therapy; this includes the renal, hepatic and haematopoietic systems. This is particularly important in neonates,especially when premature, and other infants.
Clostridium difficile associated diarrhoea has been reported with nearly all antibacterial agents, including cefoperazone and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C.difficile.
Sulbactam/cefoperazone has been effectively used in infants. It has not beenextensively studied in premature infants or neonates. Therefore, in treating premature infants and neonates, the potential benefits and possible risks involved should beconsidered before instituting therapy.
Cefoperazone does not displace bilirubin from plasma protein binding sites.
A reaction characterized by flushing, sweating, headache and tachycardia has been reported when alcohol was ingested during and as late as the fifth day aftercefoperazone administration. A similar reaction has been reported with certain other cephalosporins and patients should be cautioned concerning the ingestion of alcoholic beverages in conjunction with the administration of sulbactam/cefoperazone. For patients requiring artificial feeding orally or parenterally, solutions containing ethanol should be avoided.
Drug Laboratory Test interactions
A false positive reaction for glucose in the urine may occur with Benedicts or Fehlings solution.
Please refer to DOSAGE AND ADMINISTRATION.
In severe hepatic dysfunction, therapeutic concentrations of cefoperazone areobtained in the bile and only a 2- to 4-fold increase in the half-life is seen. Dose modification may be necessary in case of severe biliary obstruction, severe hepatic disease or in case of renal dysfunction coexistent with either of those conditions.
In patients with hepatic dysfunction and concomitant renal impairment, cefoperazone serum concentrations should be monitored and dosage adjusted as necessary. In these cases, dosage should not exceed 2 g/day of cefoperazone without close monitoring of serum concentrations.
There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Only small quantities of sulbactam and cefoperazone are excreted in human milk. Although both drugs pass poorly into breast milk of nursing mothers, caution should be exercised when sulbactam/cefoperazone is administered to anursing mother.
There are no significant changes in the pharmacokinetics of the components ofsulbactam/cefoperazone, compared to adult values. The mean half-life in children has ranged from 0.91 to 1.42 hours for sulbactam and from 1.44 to 1.88 hours for cefoperazone.
Sulbactam/cefoperazone has been effectively used in infants. It has not been extensively studied in premature infants or neonates. Therefore, in treating premature infants and neonates potential benefits and possible risks involved should be considered before instituting therapy.
Both sulbactam and cefoperazone exhibited a longer half-life, lower clearances and larger volumes of distribution when compared to data from normal volunteers. The pharmacokinetics of sulbactam correlated well with the degree of renal dysfunction while for cefoperazone, there was a good correlation with the degree of hepaticdys function.
Sulbactam/cefoperazone is generally well tolerated. The majority of adverse events are of mild or moderate severity and are tolerated with continued treatment. The most frequent side effects observed with sulbactam/cefoperazone have beengastrointestinal. others include dermatologic reactions, headache, injection pain, chills, and anaphylactoid reactions.
In pooled clinical trial data from comparative and non-comparative studies in approximately 2,500 patients, the following was observed:
Gastrointestinal: As with other antibiotics, the most frequent side effects observed with sulbactam/cefoperazone have been gastrointestinal. Diarrhoea/loose stools (3.9%) have been reported most frequently, followed by nausea and vomiting (0.6%).
Dermatological Reactions: As with all penicillins and cephalosporins, hypersensitivity manifested by maculopapular rash (0.6%) and urticaria (0.08%) has been reported. These reactions are more likely to occur in patients with a history of allergies, particularly to penicillin.
Haematological Reactions: Slight decrease in neutrophils (0.4%) has been reported. As with other beta-lactam antibiotics, reversible neutropenia (0.5%) may occur with prolonged administration. Some individuals developed a positive direct Coombs test (5.5%) during treatment. Decreased haemoglobin (0.9%) or haematocrit (0.9%) have been reported. Transient eosinophilia (3.5%) and thrombocytopenia (0.8%) have occurred, and hypo-prothrombinaemia (3.8%) has been reported.
Miscellaneous: Headache (0.04%), fever (0.5%), injection pain (0.08%) and chills (0.04%).
Laboratory Abnormalities: Transient elevations of liver function tests, SGOT (5.7%), SGPT (6.2%), alkaline phosphatase (2.4%) and bilirubin (1.2%) levels have been noted.
Local Reactions: Sulbactam/cefoperazone is generally well tolerated following intramuscular administration. Occasionally, transient pain may follow administration by this route. As with other cephalosporins and penicillins, when sulbactam/cefoperazone is administered via an intravenous catheter, some patients may develop phlebitis (0.1%) at the injection site.
The following additional undesirable effects have been reported:
General: Anaphylactoid reaction (including shock)
Gastrointestinal: Pseudomembranous colitis
Skin/Appendages: Pruritus, Stevens-Johnson syndrome
Limited information is available on the acute toxicity of cefoperazone sodium and sulbactam sodium in humans. Overdosage of the drug would be expected to produce manifestations that are principally extensions of the adverse reactions reported with the drug. The fact that high cerebrospinal fluid concentrations of beta-lactam antibiotics may cause neurological effects, including seizures, should be considered. Because cefoperazone and sulbactam are both removed from the circulation by haemodialysis, these procedures may enhance the elimination of the drug from the body if overdosage occurs in patients with impaired renal function.
Solutions of sulbactam/cefoperazone and aminoglycosides should not be directlymixed, since there is a physical incompatibility between them. If combination therapy with sulbactam/cefoperazone and an aminoglycoside is contemplated, this can beaccomplished by sequential intermittent intravenous infusion, provided that a separate secondary intravenous tubing is used and that the primary intravenous tubing is adequately irrigated with an approved diluent between doses. It is also suggested that doses of sulbactam/cefoperazone be administered throughout the day at times as far removed from the administration of the aminoglycoside as possible.
Lactated Ringers Solution
Initial reconstitution with Lactated Ringer's Solution should be avoided since this mixture has been shown to be incompatible. However, a two-step dilution process involving initial reconstitution in Sterile water for injection will result in a compatible mixture when further diluted with Lactated Ringer's Solution.
Initial reconstitution with 2% lidocaine HCl solution should be avoided since this mixture has been shown to be incompatible. However, a two-step dilution processinvolving initial reconstitution in Sterile water for injection will result in a compatible mixture when further diluted with 2% lidocaine HCl solution.
Store below 25°C. Protect from light.
Reconstituted solution is stable for 7 days at 28°C and for 24 hours at 825°C.
All unused solutions should be discarded after those time periods, respectively.
Zosul 1 g: Vial of 20 ml with 5 ml Sterile water for injection
Zosul 1.5 g: Vial of 20 ml with 10 ml Sterile water for injection